^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMC-201

    i
    Other names: IMC-201, IOH-001, IOH001, IOH 001, IMC 201, IMC201
    Associations

    News

    Trials
    Company:
    Immuneoncia Therap, WuXi AppTec
    Drug class:
    PD-L1 inhibitor, CD47 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    IOH-001, a novel CD47/PD-L1 bispecific antibody, enhances anti-tumor activity in solid tumors (AACR 2022)
    IOH-001, dual-blockage of anti-CD47 and anti-PD-L1, has shown the benefits in treating some solid tumors. Bispecific antibody IOH-001 is more likely to work better in targeting tumor cells than the combination of anti-CD47 and anti-PD-L1. Preclinical efficacy results of IOH-001 provide a strong rationale for assessing therapeutic potential in clinical studies.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD47 (CD47 Molecule) • CD14 (CD14 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    PD-L1 expression
    |
    IMC-201